Catalyst Pharmaceuticals Announces Second Quarter 2015 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- Harry and Meghan surprised by King Charles' letter on their status
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Piper Jaffray Sees 'Transformational' Next 12 Months for Catalyst Pharmaceutical (CPRX)
August 11, 2015 11:05 AM EDTPiper Jaffray analyst Charles Duncan reiterated an Overweight rating and $7 price target on Catalyst Pharmaceutical Partners (NASDAQ: CPRX) after the company 2Q15 financials and a pipeline update, ending with $67.4M in cash.
"These resources should fully fund operations through Firdapse NDA approval and... More
Catyalyst Pharma (CPRX) Tops Q2 EPS by 2c
August 10, 2015 4:31 PM EDTCatyalyst Pharma (NASDAQ: CPRX) reported Q2 EPS of ($0.06), $0.02 better than the analyst estimate of ($0.08).
For earnings history and earnings-related data on Catyalyst Pharma (CPRX) click here.
... More